Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CYCLANDELATE IN THE PROPHYLAXIS OF MIGRAINE - A RANDOMIZED, PARALLEL,DOUBLE-BLIND-STUDY IN COMPARISON WITH PLACEBO AND PROPRANOLOL
Autore:
DIENER HC; FOH M; IACCARINO C; WESSELY P; ISLER H; STRENGE H; FISCHER M; WEDEKIND W; TANERI Z;
Indirizzi:
UNIV ESSEN GESAMTHSCH,DEPT NEUROL,HUFELANDSTR 55 D-45122 ESSEN GERMANY UNIV VIENNA,DEPT NEUROL VIENNA AUSTRIA UNIV ZURICH,DEPT NEUROL ZURICH SWITZERLAND CHRISTIAN ALBRECHTS UNIV KIEL,DEPT NEUROL D-2300 KIEL GERMANY MUNICIPAL HOSP FULDA GERMANY MIGRAINE CLIN DUISBURG GERMANY INST NUMER STAT COLOGNE GERMANY
Titolo Testata:
Cephalalgia
fascicolo: 6, volume: 16, anno: 1996,
pagine: 441 - 447
SICI:
0333-1024(1996)16:6<441:CITPOM>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
EFFICACY;
Keywords:
CYCLANDELATE; DOUBLE-BLIND; PLACEBO; PROPRANOLOL; PROPHYLAXIS OF MIGRAINE; TOLERABILITY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
20
Recensione:
Indirizzi per estratti:
Citazione:
H.C. Diener et al., "CYCLANDELATE IN THE PROPHYLAXIS OF MIGRAINE - A RANDOMIZED, PARALLEL,DOUBLE-BLIND-STUDY IN COMPARISON WITH PLACEBO AND PROPRANOLOL", Cephalalgia, 16(6), 1996, pp. 441-447

Abstract

Cyclandelate inhibits calcium-induced contraction of vascular smooth muscle cells, platelet aggregation induced by thrombin, platelet-activating-factor and adenosine, and also suppresses a provoked 5HT releasefrom platelets. This pharmacological profile suggests that cyclandelate may have a potential prophylactic effect in migraine. To test this hypothesis, a double-blind multicentre study was performed in 214 patients to investigate the efficacy and tolerability of cyclandelate compared to placebo and propranolol. After a 4-week baseline period, eligible patients (randomization 3:2:3) were treated for 12 weeks with daily doses of 1.200 mg cyclandelate (n=81), placebo (n=55) or 120 mg propranolol (n=78). The number of migraine attacks (greater than or equal to 50% responders) and the migraine duration/month were compared basedon the difference between baseline and the last 4 weeks of prophylactic treatment. The percentage of patients with a reduction in migraine attacks of greater than or equal to 50% treated with cyclandelate (37.0%) or propranolol (42.3%) was not significantly superior to placebo (30.9%; p>0.025). The mean duration of migraine in hours (h) per month decreased in both active treatment groups (cyclandelate: 36.8h, p=0.046; propranolol: 34.4 h, p=0.039) compared to placebo (13.7h) without reaching statistical significance (alpha/2=0.025). The clinical efficacy of cyclandelate and propranolol was comparable. Adverse experiences were reported by 13 patients (16.0%) treated with cyclandelate, by 5 patients (9.1%) treated with placebo and by 19 patients (24.4%) treatedwith propranolol. These were drug-related in 7.1% (n=6) of patients treated with cyclandelate and in 9% (n=7) of patients treated with propranolol. In summary, cyclandelate has a comparable efficacy to that ofpropranolol, an established drug of first choice in the prophylaxis of migraine. Both drugs were better than placebo, but not significantlyso. Both active treatments were well tolerated.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 01:18:46